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1. Introduction 
Colloidal vesicular carriers such as liposomes or niosomes have been extensively applied 
in drug delivery systems due to unique advantages. These vesicles can act as drug 
reservoirs and the rate of drug release can be modified by changing of their composition. 
These lipid carriers can encapsulate both hydrophilic drugs (by loading in inner space) 
and hydrophobic drugs (in lipid area). Because of their potential to carry a variety of 
drugs, these lipid vesicles have been widely used in various drug delivery systems like 
drug targeting, controlled release and permeation enhancement of drugs (Akhilesh et al., 
2011). Dermal (topical) delivery defines a targeting to the pathological sites within the 
skin with the least systemic absorption. Drug localization in this case is a crucial issue in 
the treatment of dermatological problems such as skin cancer, psoriasis, alopecia and 
acne, where the origin of disease is located in the skin (Brown et al., 2006). Topical drug 
administration has been initiated since long time to accomplish several functions on 
different skin levels (skin surface, epidermis, dermis and hypodermis). But, several 
limitations have been associated with the conventional topical preparations e.g. low 
percutaneous penetration because of the barrier function of the stratum corneum, the 
outermost layer of the skin, (Rubio et al., 2011) and absorption to the systemic circulation 
(Dubey et al., 2012). The scientific reports nowadays offer several systems that can be able 
to deliver drugs through the skin (Higaki et al., 2005). Recently niosomes are becoming 
popular in the field of topical drug delivery due to its outstanding characteristics like 
enhancing the penetration of drugs, providing a sustained pattern of drug release and 
ability to carry both hydrophilic and lipophilic drugs (Sathali et al., 2010). This chapter 
deals with the potential of niosome in topical delivery system focusing on its clinical 
approach. Skin represents a multilayered effective barricade to the penetration of drugs. 
The outer layer of skin, stratum corneum, provides a rate limiting step during 
percutaneous absorption of drug. Drug transfer across the stratum corneum is mainly a 
passive process, and thus the physicochemical properties of a permeant have a key role in 
its capability to penetrate and diffuse across the membrane. Compounds can penetrate 
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through the stratum corneum via three routes: intercellular, transcellular (paracellular), 
and transappendageal (figure 1). Once it has transferred through the epidermis, a 
compound may be carried away by the dermal blood circulation or to be transported to 
deeper tissues. The relative significance of these penetration pathways will be largely 
dependent on the physicochemical characteristics of the drug molecules, particularly the 
partition and diffusion coefficients into the protein or lipid regions (Barry, 1991). 
 
Figure 1. Possible pathways for delivery of compounds across the stratum corneum adapted from 
reference (Gašperlin et al., 2011). 
For successful dermal or transdermal delivery, a reversible overcoming of skin barrier is 
required. Therefore, many strategies have been assessed to overcome the barrier function of 
the stratum corneum and to improve drug transport into the skin  (Ghafourian et al., 2004; 
Rahimpour et al., 2012). Targeting of topically administered drugs to the different skin 
layers and appendages is becoming a main center of interest for many pharmaceutical 
research groups studying in dermatology (Nounou et al., 2008). The carrier is one of the 
most important entities required for successful targeted drug delivery (figure 2). Carriers 
will enable a drug to reach the desired pharmacological site of action at a controlled rate and 
to have a sustained duration of action. Consequently, as a vehicle for active substances and 
targeting to skin layers, surfactant based carriers such as niosomal systems are gaining more 
interest.  
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Figure 2. Carriers for topical and transdermal drug delivery adapted from reference (Venuganti et al., 
2009). 
2. Niosome 
Niosomes are microscopic lamellar structures composed of non-ionic surfactants and 
cholesterol. The niosomes have amphiphillic bilayer structure in a way that polar region is 
oriented outside and inside the vesicles where the hydrophilic drug will be entrapped and non-
polar region is formed within the bilayer where hydrophobic drug can be entrapped (Khan et 
al., 2011). The formation of vesicular system based on hydration of mixture of a single-alkyl 
chain nonionic surfactant and cholesterol was firstly reported in 1979 (Handjani-Vila et al., 
1979). Niosomes might be produced by various types of nonionic surfactants including 
polyglycerol alkyl ethers, crown ethers, ester-linked surfactants, glucosyldialkyl ethers, 
polyoxyethylene alkyl ethers, Brij, Tweens and Spans. Nonionic surfactants used to prepare 
niosomes carry no charge and are relatively nontoxic and mild to use (Azeem et al., 2009).  
2.1. Types of niosomes 
2.1.1. Proniosomes  
Proniosome is a dry granular product that can be able to form a niosome suspension after 
hydration (Hu et al., 2000). Proniosomes are developed to overcome the disadvantage of 
vesicular system. Proniosome are prepared based on the simple scheme that a mixture of 
surfactant/alcohol/aqueous phase can be used to prepare a concentrated proniosome gel, 
which can instinctively be converted to a stable niosomal dispersion by dilution with excess 
aqueous phase (Perrett et al., 1991).  
Carrier + surfactant = Proniosomes 
Proniosomes + water = Niosomes 
 Recent Advances in Novel Drug Carrier Systems 144 
2.1.2. Aspasomes 
Mixture of acorbyl palmitate, cholesterol and highly charged lipid diacetyl phosphate leads 
to the construction of vesicles named aspasomes. Aspasomes are first hydrated with 
water/aqueous solution and then sonicated to attain the niosomes. Aspasomes are suggested 
to improve the transdermal permeation of drugs. Aspasomes have also been used to reduce 
disorders caused by reactive oxygen species due to its intrinsic antioxidant property 
(Gopinath et al., 2004; Rajera et al., 2011). 
2.1.3. Vesicles in water and oil system (v/w/o)  
In this system suspension of aqueous niosomes (v/w) are emulsified into the oily phase at 
60°C to form vesicle in water in oil emulsion (v/w/o)  (Yoshida et al., 1992; Hu et al., 2000). 
Cooling to room temperature forms vesicle in water in oil gel (v/w/o gel) (Yoshioka et al., 
1992). The prepared v/w/o gel can entrap the hydrophilic active ingredients which are 
susceptible for enzymatic degradation such as proteins/proteinous drugs and also provide a 
controlled release pattern in drug delivery.  
2.1.4. Deformable niosomes 
Elastic niosomes are prepared of nonionic surfactants, ethanol and water. They show 
superior to conventional niosomes due to their capability to increase penetration efficiency 
of a compound through intact skin by passing through pores in the stratum corneum, which 
are smaller than the vesicles (figure 3). The flexibility of their structure allows them to pass 
through pores that are less than one-tenth of these vesicles (Cevc, 1996; Cevc et al., 1996).  
 
Figure 3. Mechanism of skin permeation of deformable niosome adapted from reference (Kumar et al., 2012) 
2.2. Advantages of noisome 
The major advantages of niosomes can be mentioned as: i) niosomes are biodegradable, 
biocompatible, non-toxic and non-immunogenic (Azeem et al., 2009); ii) niosomes are able to 
 
Niosomes as Carrier in Dermal Drug Delivery 145 
encapsulate large amount of materials in a small volume of vesicles (Nasr et al., 2008); iii) 
niosomes have better patient adherence and satisfication and also better effectiveness than 
conventional oily formulations (Jain et al., 2006); iv) niosomes can entrap wide range of 
chemicals (hydrophilic, lipophilic and amphiphilic drugs) due to its unique structure (Raja 
Naresh et al., 1994); v) the characteristics of niosome such as shape, fluidity and size can be 
easily controlled by changing in structural composition and method of production (Bayindir 
et al., 2010); vi) niosomes can be prescribed via different administration routes such as oral, 
parenteral and topical, etc. with different dosage forms such as semisolids, powders, 
suspensions (Malhotra et al., 1994) and vii) due to chemical stability of structural 
composition, the storage of the niosome is easy (Jain et al., 2006). In spite of several above 
mentioned merits, niosomes show some disadvantages. The aqueous suspensions of 
niosomes may undergo fusion, aggregation, leaking of entrapped drugs, and hydrolysis of 
encapsulated drugs, which lead to limited shelf life. The methods of preparation of 
multilamellar vesicles such as extrusion, sonication, are time consuming and may require 
specialized equipments for processing (Khan et al., 2011) 
2.3. Application of niosome 
Niosomes have been successfully used in drug targeting to various organs such as skin 
(Agarwal et al., 2001), brain (Abdelkader et al., 2012), liver (Baillie et al., 1986; Lala et al., 
2004), lung (Desai et al., 2002; Abd-Elbary et al., 2008) ocular systems (Pugeat et al., 1991; 
Abdelkader et al., 2012), tumor (Ruckmani et al., 2000; Shi et al., 2005) etc. Niosomes show a 
higher bioavailability than conventional dosage forms (Raja Naresh et al., 1994). Controlled 
and sustained release of drugs have been achieved by niosomes (Bayindir et al., 2010). 
Permeation of drugs through the skin has been enhanced by niosomes (Pardakhty et al., 
2007). Noisome, itself improves the stratum corneum properties both by reducing 
transepidermal water loss and skin condition by increasing smoothness via reloading lost 
skin lipids (Firthouse et al.). Niosomes can be applied for drug protection from biological 
enzymes and acid thereby increasing the drug stability (Jain et al., 2006). 
2.4. Niosomes in comparison with liposomes 
Niosomes and liposomes have similar application in drug delivery but chemically differ in 
structure units. Niosomes constitute of non-ionic surfactant whereas liposomes comprise of 
phospholipids (Khan et al., 2011). They are functionally the same, have the same physical 
properties and act as amphiphilic vesicules. Both can be used in targeted and sustained drug 
delivery system. Property of both depends upon composition of the bilayer and methods of 
their preparation (Verma et al., 2012). Studies have also shown that the function of niosomes 
in vivo is similar to that of liposomes (Hofland et al., 1994). In spite of these comparable 
characteristics, niosomes offer several advantages over liposomes: intrinsic skin penetration 
enhancing properties, higher chemical stability and lower costs (Nasr et al., 2008). Both of 
the last features make the niosome more attractive for industrial manufacturing (Hu et al., 
2000). Also, niosomes do not require special conditions such as low temperature or inert 
atmosphere during preparation and storage (Verma et al., 2012). Although the niosome 
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shows better chemical stability, the physical instability during dispersion may be 
comparable to that of the liposome. Both niosomes and liposomes are at risk of aggregation, 
fusion, drug leakage, or hydrolysis of entrapped drugs during storage (Hu et al., 2000; 
Rahimpour et al., 2012).  
3. Mechanisms of niosomal skin delivery 
Several mechanisms have been suggested to describe the ability of niosomes in transdermal 
and dermal drug delivery: i) niosomes diffuse from the stratum corneum layer of skin as a 
whole; ii) new smaller vesicles are formed in skin (re-formation of noisome vesicles). The 
water content of skin is crucial issue for interpreting and establishing this mechanism. 
Smaller diameter of lipid lamellar spaces of the stratum corneum than noisome vesicles 
makes this mechanism more meaningful (Sahin, 2007). iii) noisomes interact with stratum 
corneum with aggregation, fusion and adhesion to the cell surface which causes a high 
thermodynamic activity gradient of the drug at the vesicle-stratum corneum surface, which 
is the driving force for the penetration of lipophilic drugs across the stratum corneum 
(Ogiso et al., 1996). Scanning electron microscopy confirmed the fusion of niosome vesicles 
of estradiol on the surface of skin (Schreier et al., 1994)  iv) niosomes may modify stratum 
corneum structure which makes the intercellular lipid barrier of stratum corneum looser 
and more permeable (Fang et al., 2001); v) non-ionic surfactant itself, the composing 
ingredient of niosome, acts as a permeation enhancer and might partly contribute to the 
improvement of drug permeation from niosomes (Javadzadeh et al., 2010). The type of 
surfactant plays an important role in modification of permeation using niosome vehicles. 
Niosomes fabricated from polyoxyethylene stearyl ether and existing in the gel state did not 
enhance estradiol permeation, and those prepared from polyoxyethylene lauryl ether and 
polyoxyethylene oleyl ether, both existing as liquid crystalline vesicles, considerably 
improved transport (Hofland et al., 1991). 
4. Toxicity of niosomes 
Surfactants are suspected to show toxicity but there are virtually not enough research about 
toxicity of niosomes (Yadav et al., 2011). A study on the toxicity effect of surfactant type of 
niosomal formulations on human keratocytes showed that the ester type surfactants are less 
toxic than ether type due to enzymatic degradation of ester bounds (Hofland et al., 1991). 
Hofland et al. studied the toxicity of CxEOy surfactants via ciliotoxicity model on nasal 
mucosa (which is important for intranasal administration) and on human kerationocytes 
(which is important for the transdermal application of vesicles). The results showed that 
increase in alkyl chain length of surfactant causes a reduction in toxicity, while, increase in 
the polyoxyethylne chain length enhances ciliotoxicity. The study supposed that ciliotoxicity 
related to liquid state formation with increasing in polyoxyethylene chain length, while 
increase in alkyl chain length of surfactant leads to formation of gel which is more safe than 
liquid state (Hofland et al., 1992). In another study, vincristine, a potent anti-tumor agent, 
was loaded into niosomes and administered intravenously. Result showed a significant 
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increase in vincristine anti-tumor activity in S-180 sarcoma and Erlich ascites mouse models 
followed by reduction of its side effect such as diarrhea, neurological toxicity and alopecia 
compared with free drug (Parthasarathi et al., 1994). Toxicity effect of niosomes should be 
considered according to the intended route of delivery. For example, hemocompatibility 
studies should be carried out when the niosomes are meant to be delivered by intravenous 
route to evaluate their toxic potential (Uchegbu et al., 1997). The first in vivo experiment on 
drug delivery by means of synthetic non-ionic surfactant vesicles were carried out by Azmin 
et al. and reported that no unfavorable effects were observed in the performed experiment 
(Azmin et al., 1985). Rogerson et al. reported in vivo experiment over 70 male BALB/C mice 
and stated that no fatalities were related to niosomes. The drug associated toxicity were also 
reduced (Rogerson et al., 1987). Niosomes which have been prepared with Bola-surfactants 
showed a certain and encouraging safety and tolerability both in vitro on human 
keratinocyte cells up to an incubation time of 72 h for the different concentrations studied 
(0.01-10 µM) and in vivo on human volunteers that showed no skin erythema when 
topically treated with the drug free Bola-niosome formulation (Paolino et al., 2007).  
5. Indications for niosomes as drug carriers in dermatology 
Niosomes were formulated and patented for the dermatological purposes in 1975 for the 
first time and since then many of products were developed based on this technology and 
appeared in the market such as Lancome Noisome Plus as an anti-ageing formulation 
(Azeem et al., 2009). Recently, the topical delivery of certain drugs using niosome has been 
developed. Here, current attempts with a focus on clinical application were reviewed to 
prove the ability of niosomes as the superior topical carrier.  
5.1. Local anesthesia 
Dermatologists take benefit of topical anesthetics for decreasing pain relief prior to 
cutaneous procedures, pain associated with laser pulses, or soft tissue augmentation. 
Inefficient formulations of local anesthetics resulted in severe dermatitis, systemic toxicity, 
or inadequate local analgesia. Carafa et al. fabricated lidocaine and lidocaine hydrochloride-
loaded non-ionic surfactant vesicles using Tween 20™ and cholesterol. The ability of drug to 
diffuse through a model lipophilic membrane (Silastic™) and through mouse skin were 
studied and compared with classical liposomes and Tween 20 micelles. Dicetylphosphate 
and N-cetylpyridinium chloride were also used to prepare negatively and positively 
charged vesicles, respectively to study the effect of vesicle charge on drug encapsulation 
efficiency. Diffusion experiments indicated that the flux of charged lidocaine (lidocaine 
hydrochloride) through Silastic™ membrane was possible only after the vesicle 
encapsulation. Permeation of lidocaine hydrochloride-loaded vesicles through mouse 
abdominal skin presented a higher flux and a shorter lag time with respect to classical 
liposome formulations, whereas lidocaine permeation rate was quite similar for niosomes 
and liposome formulations. Furthermore fluorescence quenching study showed that 
positive and negative charged vesicles had negligible entrapment efficiency of drug, at pH 
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5.5 compare with neutral vesicles (Tween 20 and cholesterol). The importance of non-ionic 
surfactant vesicles in dermal delivery of charged local anesthetics is concluded in this study 
(Carafa et al., 2002).  
5.2. Psoriasis 
Psoriasis is a chronic inflammatory condition of the skin which may drastically undermined 
the patient quality of life. Psoriasis, a T-lymphocyte-mediated autoimmune disease of the 
dermis and epidermis, is characterized by leukocyte infiltration into the skin and localized 
deregulated skin growth, which leads to the development of scaling erythematous plaques 
(Dubey et al., 2007). Although psoriasis is rarely life-threatening, it causes an unpleasant 
appearance that makes the patients to miss their confidence and suffer from itching, painful 
and disfiguring skin lesions. Methotrexate, anthralin, corticosteroids, coal tar, vitamin D3 
analogs, tacrolimus and retinoids are administered topically for psoriasis treatment (Su et 
al., 2008). Topical therapy is the commonly used in patients, even though the use of topical 
formulations based on conventional excipients shows some disadvantages that limit 
considerably their use in therapy (Puglia et al., 2012). With the use of niosomes as carrier for 
topical drug delivery, the possibility to improve efficacy and safety of the topical products 
has improved manifold. Dithranol, one of the key medicines in the topical treatment of 
psoriasis, has staining, burning, irritating and necrotizing effects on the normal and also the 
diseased skin. Entrapment of dithranol in niosomal and liposomal systems could be 
achieved after optimizing the various process and formulation variables. These systems 
presented size stability and improved drug permeation properties. Although the in vitro 
study using laca mice abdominal skin shows higher skin penetration for vesicular systems 
compared with the cream base but niosomal vesicular systems had three times less 
percutaneous permeation of dithranol compared with liposomal formulation (Agarwal et 
al., 2001). Methotrexate is an antifolate class of anti-neoplastic medicine which is commonly 
used in the psoriasis therapy. The systemic administration of this drug causes several side 
effects such as hepatic toxicity. Dermal delivery of methotrexate offers a valuable alternative 
way to reduce its adverse effects (Javadzadeh et al., 2011). The double-blind placebo-
controlled study of methotrexate-loaded niosomal vesicles in chitosan gel on healthy human 
volunteers and psoriasis patients carried out and its efficacy compared with marketed 
methotrexate gel. The irritation and skin sensitivity of formulations were assessed via 
human repeated insult patch test (HRIPT). The HRIPT method did not yield any significant 
sensitization or irritation on healthy human volunteers. The severity of the lesions of 
psoriasis was assessed via Psoriasis Area Severity Index (PASI). The global score used to 
assess the outcome of therapy (on a scale of 0-5), where score of 5 indicates the worsening of 
lesion and score 0 indicates complete clearance of lesion. There was a three times reduction 
in PASI scores after 12 weeks of niosomal methotrexate gel. The results of study offer 
niosomal formulation of methotrexate for dermal treatment of psoriasis due to its better 
clinical efficacy, tolerability and patient compliance (Lakshmi et al., 2007). Urea is an 
emollient topically used for the non-surgical removal of dystrophic nails in cases of fungal 
infections for decades and used as a penetration enhancer for the topical corticosteroid 
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treatment of hyperkeratotic psoriatic plaques (Draelos, 2008). Urea may increase ability of 
skin to retain water due to hygroscopic effect. The same group in another study 
encapsulated urea into niosomes and prepared a gel using chitosan polymer, to test the 
same on healthy human volunteers to check the irritation on the skin and to study its clinical 
effectives on psoriasis patients. Niosomes prepared using span 60 showed a better 
entrapment than other spans. Better diffusion of drug through the human skin and skin 
drug deposition were concluded from niosomal gel in comparison to plain gel. The 
niosomal urea gel and plain gel did not produce any irritation of the human skin. The gels 
were assessed on psoriasis patients with less than 25% severity of any types of psoriasis. The 
niosomal gel showed a significant decrease in the lesion (p<0.05) than plain urea gel. It is 
suggested that chitosan gel can be used as an adjuvant in the treatment of psoriasis due to 
antifungal and anti-inflammatory effect of chitosan that supported the action of urea 
(Lakshmi et al., 2011).  
5.3. Whitening effect  
The attractiveness of pigment-lightening cosmeceuticals comes from the desire to not only 
fade pigmentation but also to even lighten skin tone (Choi et al., 2006). N-acetyl 
glucosamine (NAG), which is an amino sugar that occurs widely in nature and essential 
component of dermal tissues, is well-known for its role as a precursor of hyaluronic acid, a 
key structural composition of skin. NAG shown to inhibit melanin production in 
melanocyte culture, thus has a potential to reduce hyperpigmentation by topical 
administration (Bissett et al., 2007). To improve NAG penetration into the skin Shatalebi et 
al. encapsulated it into niosomes and investigated its flux across excised rat skin using Franz 
diffusion cells. All formulations significantly enhanced the drug localization in the skin, as 
compared to NAG hydroalcoholic solution. Application of negatively charged dicetyl 
phosphate was suggested the reason for relatively high amount of entrapment of the very 
water soluble NAG. This study showed the potential of niosomes for improved NAG 
localization in the skin, as needed in hyperpigmentation disorders (Shatalebi et al., 2010). 
Ellagic acid, a polyphenol widely found in plants such as pomegranates, inhibits tyrosinase 
by its copper chelation. It may selectively inhibit melanin synthesis only in UV-activated 
melanocytes (Choi et al., 2006). A niosomal formulation of ellagic acid was developed from 
the mixture of Span 60 and Tween 60 for its dermal delivery. Skin distribution study 
revealed that the ellagic acid-loaded niosomes showed more efficient delivery of ellagic acid 
through human epidermis and dermis than ellagic acid solution.  The results pointed out 
that the Span 60 and Tween 60 niosomes may be a potential carrier for dermal delivery of 
ellagic acid (Junyaprasert et al., 2011).  
5.4. Vitiligo   
Vitiligo is an acquired idiopathic, dermatological disorder described by well-
circumscribed milky white macules in which melanocytes in the skin are damaged. 
Although vitiligo is not a life threatening issue but it might have an important negative 
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impaction on the quality of life, even leading to attempted suicide in some cases  
(Nogueira et al., 2009; Bhawna et al., 2010). Application of novel dermal drug delivery 
systems can play a key role in vitiligo treatment because side-effects or poor efficacy of 
conventional topical dosage forms affect their utility and patient compliance (Bhawna et 
al., 2010). Human tyrosinase gene is responsible for the production of tyrosinase, an 
enzyme implicates in melanogenesis. The defect of tyrosinase gene is one of the reasons 
for depigmented skin or vitiligo (Zhang et al., 2005; Kingo et al., 2007). Manosroi et al. 
prepared elastic cationic niosomes (Tween 61/Cholesterol/ dimethyl dioctadecyl 
ammonium bromide at 1:1:0.5 molar ratio) for the effective dermal delivery of pMEL34 
(tyrosinase encoding plasmid). Percutaneous absorption of formulation was investigated 
through exercised rat skin by Franz diffusion cells during 6 hours. The flux of pMEL34-
loaded elastic niosomes was more than non-elastic niosomes in viable epidermis and 
dermis, while only pMEL34 loaded in elastic cationic noisome was observed in the 
receiver solution. By application of pMEL34-loaded elastic cationic niosomes in melanoma 
cell lines showed about four times higher tyrosinase gene expression than the free and the 
loaded plasmid in nonelastic niosomes means higher tyrosinase activity for efficient 
topical delivery in vitiligo therapy (Manosroi et al., 2010). In another study, luciferase 
plasmid (pLuc) was encapsulated in non-elastic and elastic cationic nanovesicles 
(niosomes and liposomes) and its transdermal absorption was investigated through rat 
skin follow by stratum corneum stripping or iontophoresis techniques. Free pLuc with or 
without the stratum corneum stripping and iontophoresis techniques and pLuc-loaded in 
nonelastic vesicles without the application techniques could not penetrate skin. Though, 
the elastic vesicles even without any application techniques can increase the transdermal 
absorption of pLuc. In case of elastic vesicles, the pLuc-loaded niosomes provided higher 
pLuc flux than that in liposomes. After 6 hours, pLuc encapsulated in nanovesicles with 
the iontophoresis application was still intact, but the free pLuc was degraded. Result of 
this study has showed the superior delivery of pLuc thorough skin by loading in 
niosomes, together with the application of iontophoresis, which can be used as a novel 
method to deliver genetic materials via dermal administration in gene therapy. 
Specifically, elastic cationic niosomes appeared to be a more promising approach since no 
additional equipment is required (Manosroi et al., 2009). Both mentioned studies 
demonstrated the potential application of elastic cationic niosomes as an efficient topical 
delivery for the purpose of gene therapy. 
5.5. Cutaneous inflammation 
5.5.1. Non - steroidal anti-inflammatory drugs (NSAIDs) 
Celecoxib, a selective COX–2 inhibitor and most commonly used drug in the treatment of 
arthritis was embedded in niosomal gel for the purpose of sustained and site-specific 
delivery. In vitro, ex-vivo and in vivo studies were carried out through albino rats to 
compare the efficiency of formulation with carbopol gel as control formulation. Niosomal 
gel showed 6.5 times higher drug deposition in deep skin layer and muscle compare with 
carbopol gel indicating better drug localization with niosomal gel. A significant reduction of 
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rat paw edema was resulted after administration of niosomal formulation compared to that 
after application of conventional gel confirming better skin permeation and deposition of 
celecoxib from niosomes. The authors concluded that niosomal gel formulation has great 
potential for improving site specific delivery, skin accumulation and prolonging release of 
celecoxib (Kaur et al., 2007). Multilamellar liposomes and niosomes of aceclofenac, a potent 
analgesic, anti-pyretic and anti-inflammatory agent were prepared and a comparative study 
was done between them through evaluation of entrapment efficiency, particle size, shape, 
differential scanning calorimetry, in vitro drug release and 3 months stability study. Results 
proved that niosomes have better stability than liposomes. Both vesicular systems showed 
considerable sustained anti-inflammatory activity compared with the commercial product, 
however niosomes being superior to liposomes as clearly showed by both oedema rate and 
inhibition rate percentages assessed by the rat paw oedema technique (Nasr et al., 2008). 
Proniosomal formulation of gugulipid (anti-inflamatory agent) was fabricated and 
characterized through in vitro drug release study and invivo anti-inflammatory activity via 
carrageenan-induced rat hind-paw method. In vitro study of proniosomal gel throught 
semi-permeable membrane exhibit  the initial faster release followed by slow sustained 
release of gugulipid for 8 h. Gugulipid incoporated proniosomal gel showed good anti-
inflammatory activity but not as good as commercial product diclofenac 
(Voveran®Emulgel). The authors state that proniosome formulation improve anti-
inflammatory activity of gugulipids comparable to topical NSAIDs (Goyal et al., 2011). A 
niosome based transdermal drug delivery of nimesulide was prepared by lipid film 
hydration technique using different nonionic surfactants, Tweens® and Spans® and 
optimized for highest percent drug entrapment. Formulations were extensively 
characterized and evaluated in-vitro performance followed by in-vivo evaluation in rats by 
carrageenan induced rat paw edema method. The results were compared with plain drug 
gel, niosomally entrapment drug in carbopol gel base and marketed formulation. The 
percentage of edema inhibition was the highest for niosomal nimesulide gel after 24 hours 
more than five and three times than plain drug gel and market formulation, respectively. 
The results of this research suggest that niosomal formulation can offer consistent and 
prolonged anti-inflammatory effect and may improve therapeutic index of the formulation 
and is also expected to minimize the side effect due to drug localization at the site of action 
(Shahiwala et al., 2002).  
5.5.2. Glucocorticosteroids 
Topical corticosteroids are administered for the variety of dermatological disorders. 
Application of corticosteroid in proper carrier may help to prolonged action, subsequently 
less frequent administration and reduction of adverse effects. In a study, clobetasol 
propionate, a potent corticosteroid acts as an anti-inflammatory and anti-pruritic, was 
loaded in niosomal gel and its performance was compare with marketed gel and pure drug 
in term of in vitro drug release and in vivo pharmacodynamic studies. The results showed 
that the niosomal gel formulation provided a prolonged action due to the entrapment of 
clobetasol in vesicles (Lingan et al., 2011).  
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5.5.3. Antihistamines 
Hence antihistamines are frequently administered as first line treatment to reduce the 
symptoms of urticaria pigmentosa because histamine is the single most important mediator 
involved (Osvaldo et al., 2010). The conventional oral administration of hydroxyzine 
hydrochloride (an antihistamine) causes CNS sedation, dry mouth and tachycardia whereas 
topical use in the form of semisolid dosage forms would lead to systemic side effects 
(Elzainy et al., 2003). A modified proniosomal gel of hydroxyzine hydrochloride was 
prepared by coacervation phase separation technique with different combination of non-
ionic surfactants (Tweens and Spans) with phospholipids. Statistical experimental design 
was applied to optimize the various formulation variables. The optimized formulations 
were evaluated in vitro, ex vivo permeation, skin deposition, skin irritation and stability 
studies. The three months stability at refrigeration temperature and quite high 
encapsulation efficiency (95%) and drug deposition in the stratum corneum in 24 h (90%) 
were found for optimized formulation. The results indicated that modified proniosomal 
formulations of hydroxyzine hydrochloride were appropriate for topical drug delivery 
system for the treatment of localized urticarial (Rita et al., 2012). This formulation 
potentially improves drug penetration into the stratum corneum and localizes the drug 
within the dermoepidermal layers which would offer prompt onset and prolonged duration 
of action due to maintenance of effective concentrations in the skin, while systemic serum 
concentrations would be low (Carafa et al., 1998; Kirjavainen et al., 1999; Elzainy et al., 2003). 
Chlorpheniramine maleate is one of the most commonly used antihistamines and topically 
administered for skin disorders such as sunburns, urticaria, angioedema, pruritus, and 
insect bites. The proniosomes containing Span 40/lecithin/cholestrol formulated by ethanol 
showed optimum stability, loading efficiency, and particle size and appropriate release 
kinetic for percutaneous delivery of chlorpheniramine maleate. Ease of preparation and use 
of proniosomes were introduced as the greatest advantages provided by these types of 
dosage forms (Varshosaz et al., 2005).  
5.6. Hair loss - Alopecia 
The pilosebaceous unit including sebaceous gland, hair follicle and hair shaft has a unique 
biochemistry, metabolism and immunology. Targeted drug delivery may improve current 
therapeutic approaches to treat diseases of follicular origin (Weiner, 1998). In an increasing 
amount of topical studies, niosomes have been revealed to target drug delivery to the 
pilosebaceous unit. Androgenic alopecia (male pattern hair loss) is the most common reason 
of hair loss in men and characterized by the progressive hair thinning in genetically 
susceptible men (Jung et al., 2006). Semi-purified fraction of Oryza sativa contains the 
unsaturated fatty acids such as gamma-linolenic acid, linoleic acid and oleic acid have been 
proved to have anti-hair loss activity by inhibition of 5a-reductase type 1 (a key enzyme of 
androgenic alopecia) in DU-145 cell lines (Ruksiriwanich et al., 2011). Manosroi et al. 
prepared cationic niosomes (for higher stability) encapsulated with this extract and 
investigated physicochemical characteristics and transfollicular penetration of niosomes 
through porcine skin using follicular closing technique by Franz diffusion cells. The result of  
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this study confirmed efficient transfollicular delivery of unsaturated fatty acids using 
cationic niosomes as well as the advantage of low systemic effect than the neutral niosomes 
(Manosroi et al., 2012). Thai Lanna medicinal plants have been reported to improve hair 
growth and reduce hair loss owing to increase the blood circulation, anti-fungal, anti-
bacterial, and anti-oxidation of the hair roots. But, the extracts of these plants are naturally 
not stable and are problematic to be absorbed through hair follicles. Niosomal formulation 
containing the Thai Lanna plant extracts, such as turmeric, chili, ginger and Tong-Pan-
Chang extract incorporated in gel was fabricated and tested in 20 human volunteers (9 
males and 11 females). Results showed a significant increase in hair density and a decrease 
in hair loss without any irritation in all subjects from the 8-week application (p<0.01) in non-
heredity alopecia volunteers, with non-differences in male and female volunteers. This in 
vivo study confirms potential of niosomes carrier for topical application of Thai Lanna 
medicinal plants for anti-hair loss (Manosroi et al., 2008). The enzyme 5a-reductase, 
responsible for production of dihydrotestosterone from testosterone in hair follicles, which 
is supposed to be the reason of androgenetic alopecia, can be inhibited by finasteride. 
Finasteride shows several unwanted systemic adverse effects which will be reduced if it acts 
locally in the hair follicles (Javadzadeh et al., 2010). Tabbakhian et al. studied dermal 
application of finasteride-containing vesicles (niosomes and liposomes) for increasing drug 
concentration at the pilosebaceous units, as compared with finasteride hydroalcoholic 
solution. Both in vitro permeation of 3H-finasteride through hamster flank skin and in vivo 
deposition studies in hamster ear demonstrated the potentials of liquid-state niosomes and 
liposomes for successful delivery of finasteride to the pilosebaceous units compared with 
hydroalcoholic solution while optimized niosomal formulation also showed higher 
targeting ration than liposomal vesicles (Tabbakhian et al., 2006).  Minoxidil, the most 
commonly used medicine for the treatment of androgenic alopecia with unknown 
mechanism of action on hair follicles (Messenger et al., 2004) were encapsulated into 
noisome and liposome vesicles. The percutaneous absorption study was carried out in vitro 
using vertical diffusion Franz cells using human skin and the results compared with 
dissolved minoxidil in propylene glycol–water–ethanol solution as a control. Although 
penetration of niosomal minoxidil in epidermal and dermal layers was greater than control 
solution but lower than liposomal formulations. These differences suggested to be attributed 
to the smaller size and the greater potential targeting to skin and skin appendages of 
liposomal carriers, which enhanced globally the skin drug delivery. This work generally 
suggests that niosomes and liposomes have a proper potential for drug dermal targeting 
and could be considered as a reasonable and practicable therapeutic approach to skin 
diseases such as hair loss (Mura et al., 2007). In a another study the effects of niosomal 
minoxidil formulation on the drug penetration in hairless mouse skin were investigated by 
in vitro permeation experiments, and the results compared with control minoxidil 
hydroalcoholic solution and a leading commercial topical formulation “MinoxylTM” 
containing 5% minoxidil and 1% dexpentanol. The result of study showed niosomal 
formulations increased the percentage of dose accumulated in the skin (1.03±0.18 to 
19.41±4.04%) compared with control and commercial formulations (0.48±0.17 and 0.11±0.03 
%, respectively). Physical stability of niosomal formulations which was evaluated for three 
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month at refrigerator temperature (2–8 °C) have shown a fairly high retention of minoxidil 
inside the vesicles (80%). The authors finally proposed that these niosomal formulations 
could be used as a feasible cargo carrier for the dermal delivery of minoxidil and promising 
approach in treatment alopecia (Balakrishnan et al., 2009). Recently minoxidil-loaded 
niosomes were prepared with series of surfactant and cholesterol in different molar ratio by 
ethanol injection method. Surfactant screening exhibited that only Span 20, Span 60 and 
Tween 20 with cholesterol have ability of nano size vesicle formation and  Span 60 was 
shown to be a better surfactant for niosomal stable form with maximum entrapment 
efficiency (31.27±1.5 %) and minimal particle size (approx. 219 nm). The in vitro skin 
permeation and deposition study of minoxidil-loaded niosomal gel formulation prepared 
with 1:2 ratio of Span 60 and cholesterol showed significant improvement in skin 
accumulation (more than eightfold) as compared with plain minoxidil gel (17.21±3.2 and 
2.26±1.3 %, respectively). Result of study demonstrates an increase in cholesterol 
concentration in niosome vesicles enhance minoxidil skin retention and effect on 
entrapment efficiency as well as size of niosomes to better cutaneous treatment. It was also 
concluded that the developed niosomal formulation could be a suitable option for cutaneous 
targeting of minoxidil (Mali et al., 2012).  
5.7. Acne 
Acne is the most common skin disease of multifactorial origin with an incidence of 70 - 80% 
in adolescence. While topical therapy has an important role in acne treatment, side effects 
associated with several topical antiacne agents affect their efficacy and patient satisfaction. 
Niosomes, capable of great features for skin administration, can play an essential role in 
improving the dermal delivery of antiacne agents by increasing their topical localization 
with an associated reduction in their adverse effects  (Maibach et al., 2005). Benzoyl 
peroxide is a macrolide antibiotic generally applied for the management of acne either alone 
or in combination with other antiacne agents. Dermal administration of benzoyl peroxide 
causes side effects such as skin redness, itching, irritation and edema which lead to 
discomfort and ignorance of therapy and outcomes in no profit or emergence of resistant to 
microorganisms. In a study, niosomal benzoyl peroxide incorporated into HPMC gel 
designed and optimized by partial factorial design. Ex vivo release study on human cadaver 
skin showed increase in drug skin retention, extended drug release and improved 
permeation of drug across the skin which in turn will reduce the toxicity of drug and 
enhance the therapeutic efficacy (Vyas et al., 2011). Gallidermin is mainly promising for the 
dermal and cosmetic treatment of acne in human medicines because of its greatly active 
against Propionibacterium acnes and treatment of multidrug resistant Staphylococcus Aureus 
strains, which is a snowballing problem especially in the hospitals (Kempf et al., 1999). 
Gallidermin has limited absorption through skin and chemical instability due to its large 
molecular structure and peptide nature, respectively (Manosroi et al., 2005). Anionic 
niosomal gallidermin composed of tween 61/cholesterol /dicetylphosphate prepared and 
antibacterial activity of formulations against Propionibacterium acnes and Staphylococcus 
Aureus assayed with macrodilution method to determine the minimal concentration of the 
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sample necessary to inhibit or kill the microorganisms. Result of study demonstrates 
gallidermin loaded in niosomes offered lower antibacterial activity against tested 
microeorganisms compare with unloaded gallidermin due to the niosomes protecting role 
and making a sustained release of drug. Niosomal furmulation of gallidermin in gel showed 
more chemically stable at high temperatures and two fold higher cumulative amounts in 
viable epidermis and dermis of rat skin than aqueous solution of gallidermin. This study 
suggests that anionic niosomes of gallidermin can be considered as a superior topical 
antibacterial formulation because of chemical stability and high skin localization with no 
threat of systemic effect (Manosroi et al., 2010). Trans-retinoic acid or tretinoin, a vitamin A 
metabolite, is widely used in the topical treatment of various skin diseases such as acne, 
psoriasis and photoaging. But, high chemical instability and skin irritation strongly limited 
its administration for topical delivery (Ridolfi et al., 2011). Transdermal delivery of tretinoin-
loaded niosomal and liposomal formulation was studied through the newborn pig skin 
using Franz diffusion cells and compared with commercial formulation (RetinA®). The  
effect of charge on the performance niosomes was studied by the preparation of niosomes 
with either stearylamine and dicetylphosphate as a positive and negative charge  
inducer, respectively. Small unilamellar negatively charged niosomal formulations 
saturated with tretinoin showed more upper cutaneous drug retention than both 
commercial and liposomal formulation. Result of this study demonstrates cutaneous 
delivery of tretinoin is powerfully affected by vesicle morphology, composition and 
thermodynamic activity of the drug (Manconi et al., 2006). The ability of niosomes as topical 
carriers capable of improving the stability of photosensitive drugs was studied by 
comparing the chemical stability of tretinoin in methanol and in vesicular suspensions 
exposed both to UV and artificial daylight conditions. Liposomes were also prepared and 
compared with niosomes. In order to evaluate the influence of vesicle structure on the 
photostability of tretinoin, tretinoin-loaded vesicles were prepared by the film hydration 
method, extrusion technique and sonication. Methanol dissolved tretinoin degraded 
immediately after UV irradiation while the loaded drug into vesicles showed a considerable 
reduction of the photodegradation process. The photoprotection provided by vesicles varied 
depending on the vesicle structure and composition. In addition, unilamellar vesicles 
showed a higher protection of tretinoin than the multilamellar ones. Unilamellar niosomes 
made from Brij®30 were the formulations with the highest protection of tretinoin (Manconi 
et al., 2003). In another study, the antiacne activity of the mixture of aromatic volatile oil 
extracted from Thai medicinal plants enhanced with encapsulating into nano sized niosomal 
vesicles (Manosroi et al., 2008). Slow penetration of drug through skin is the main 
disadvantage of transdermal route of delivery. An increase in the penetration rate has been 
achieved by transdermal delivery of erythromycin incorporated in niosomes for acne 
therapy (Jayaraman et al., 1996).  
6. Conclusion  
Niosomal drug delivery systems have been demonstrated to be promising controlled drug 
delivery systems for percutaneous administration. Niosomes also offer successful drug 
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localization in skin which are relatively non-toxic and stable. This advantage of niosomes 
has the potential of strengthening the efficacy of the drug accompanying with reducing its 
adverse effects associated with drug systemic absorption. Drug-associated challenges such 
as physical and chemical instability is also can be protected by vesicular carriers. Niosomes 
appeared to be a well preferred drug delivery system over liposome as niosomes being 
stable and cost-effective. Hence, many topical drugs may be developed using niosomal 
systems. But there are still some challenges in this area. Although some new approaches 
have been developed to overcome the problem of drug loading, it is still remain to be 
addressed. The researchers should be more alert in the selection of suitable surfactant for 
noisome preparation due to this fact that the type of surfactant is the main parameter 
affecting the formation of the vesicles, their toxicity and stability.  
Author details 
Yahya Rahimpour 
Biotechnology Research Center and Student Research Committee,  
Tabriz University of Medical Sciences, Tabriz, Iran 
Hamed Hamishehkar 
Pharmaceutical Technology Laboratory, Drug Applied Research Center,  
Tabriz University of Medical Sciences, Tabriz, Iran 
7. References 
Abd-Elbary, A.; El-laithy, H.M. & Tadros, M.I., (2008). Sucrose stearate-based proniosome-
derived niosomes for the nebulisable delivery of cromolyn sodium. Int J Pharm, Vol. 
357, No. 1-2, pp. 189-198, ISSN:  0378-5173. 
Abdelkader, H.; Ismail, S.; Hussein, A.; Wu, Z.; Al-Kassas, R. & Alany, R.G., (2012). 
Conjunctival and corneal tolerability assessment of ocular naltrexone niosomes and 
their ingredients on the hen's egg chorioallantoic membrane and excised bovine cornea 
models. Int J Pharm, Vol. 432, No. 1-2, pp. 1-10, ISSN:  0378-5173. 
Abdelkader, H.; Wu, Z.; Al-Kassas, R. & Alany, R.G., (2012). Niosomes and discomes for 
ocular delivery of naltrexone hydrochloride: morphological, rheological, spreading 
properties and photo-protective effects. Int J Pharm, Vol. 433, No. 1-2, pp. 142-148, 
ISSN:  0378-5173. 
Agarwal, R.; Katare, O.P. & Vyas, S.P., (2001). Preparation and in vitro evaluation of 
liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm, Vol. 
228, No. 1, pp. 43-52, ISSN:  0378-5173. 
Akhilesh, D.; Hazel, G. & Kamath, J.V., (2011). Proniosomes – A propitious provesicular 
drug carrier International Journal of Pharmacy and Pharmaceutical Science Research, Vol. 1, 
No. 3, pp. 98-103, ISSN:  2249-0337  
Azeem, A.; Anwer, M.K. & Talegaonkar, S., (2009). Niosomes in sustained and targeted drug 
delivery: some recent advances. J Drug Target, Vol. 17, No. 9, pp. 671-689, ISSN:  1061-
186X. 
 
Niosomes as Carrier in Dermal Drug Delivery 157 
Azmin, M.N.; Florence, A.T. & Handjani-Vila, R.M., (1985). The effect of non-ionic surfactant 
vesicle (niosome) entrapment on the absorption and distribution of methotrexate in 
mice. J Pharm Pharmacol, Vol. 37, No. 4, pp. 237-242, ISSN:  0022-3573 
Baillie, A.J.; Coombs, G.H.; Dolan, T.F. & Laurie, J., (1986). Non-ionic surfactant vesicles, 
niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J 
Pharm Pharmacol, Vol. 38, No. 7, pp. 502-505, ISSN:  0022-3573. 
Balakrishnan, P.; Shanmugam, S.; Lee, W.S.; Lee, W.M.; Kim, J.O.; Oh, D.H.; Kim, D.D.; Kim, 
J.S.; Yoo, B.K. & Choi, H.G., (2009). Formulation and in vitro assessment of minoxidil 
niosomes for enhanced skin delivery. Int J Pharm, Vol. 377, No. 1, pp. 1-8, ISSN:  0378-
5173. 
Barry, B.W., (1991). Lipid-Protein-Partitioning theory of skin penetration enhancement. J 
Control Release, Vol. 15, No. 3, pp. 237-248, ISSN:  0168-3659. 
Bayindir, Z.S. & Yuksel, N., (2010). Characterization of niosomes prepared with various 
nonionic surfactants for paclitaxel oral delivery. J Pharm Sci, Vol. 99, No. 4, pp. 2049-
2060, ISSN:  1520-6017. 
Bhawna, G.; Abir, S.; Amit, B. & Om, K., (2010). Topical treatment in vitiligo and the 
potential uses of new drug delivery systems. Indian J Dermatol Venereol Leprol, Vol. 76, 
ISSN: 0378-6323. 
Bissett, D.L.; Robinson, L.R.; Raleigh, P.S.; Miyamoto, K.; Hakozaki, T.; Li, J. & Kelm,  
G.R., (2007). Reduction in the appearance of facial hyperpigmentation by  
topical N-acetyl glucosamine. J Cosmet Dermatol, Vol. 6, No. 1, pp. 20-26, ISSN:  1473-
2165. 
Brown, M.B.; Martin, G.P.; Jones, S.A. & Akomeah, F.K., (2006). Dermal and transdermal 
drug delivery systems: current and future prospects. Drug Deliv, Vol. 13, No. 3, pp. 175-
187, ISSN:  1071-7544. 
Carafa, M.; Santucci, E.; Alhaique, F.; Coviello, T.; Murtas, E.; Riccieri, F.; Lucania, G. & 
Torrisi, M.R., (1998). Preparation and properties of new unilamellar non-ionic/ionic 
surfactant vesicles. Int J Pharm, Vol. 160, No. 1, pp. 51-59, ISSN:  0378-5173. 
Carafa, M.; Santucci, E. & Lucania, G., (2002). Lidocaine-loaded non-ionic surfactant vesicles: 
characterization and in vitro permeation studies. Int J Pharm, Vol. 231, No. 1, pp. 21-32, 
ISSN:  0378-5173. 
Cevc, G., (1996). Transfersomes, liposomes and other lipid suspensions on the skin: 
permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev 
Ther Drug Carrier Syst, Vol. 13, No. 3-4, pp. 257, ISSN:  0743-4863. 
Cevc, G.; Blume, G.; Schätzlein, A.; Gebauer, D. & Paul, A., (1996). The skin: a pathway for 
systemic treatment with patches and lipid-based agent carriers. Adv Drug Deliv Rev, 
Vol. 18, No. 3, pp. 349-378, ISSN:  0169-409X. 
Choi, C.M. & Berson, D.S., (2006). Cosmeceuticals. Semin Cutan Med Surg, Vol. 25, pp.163-
168, ISSN: 1085-5629 
Desai, T.R. & Finlay, W.H., (2002). Nebulization of niosomal all-trans-retinoic acid: An 
inexpensive alternative to conventional liposomes. Int J Pharm, Vol. 241, No. 2, pp. 311-
317, ISSN:  0378-5173. 
 Recent Advances in Novel Drug Carrier Systems 158 
Draelos, Z.D., (2008). New channels for old cosmeceuticals: aquaporin modulation. Journal of 
cosmetic dermatology, Vol. 7, No. 2, pp. 83-83, ISSN:  1473-2165. 
Dubey, A.; Prabhu, P. & Kamath, J., (2012). Nano Structured lipid carriers: A Novel Topical 
drug delivery system. Int J PharmTech Res, Vol. 4, No. 2, pp. 705-714, ISSN:  0974- 
4304. 
Dubey, V.; Mishra, D.; Dutta, T.; Nahar, M.; Saraf, D.K. & Jain, N.K., (2007). Dermal and 
transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release, 
Vol. 123, No. 2, pp. 148-154, ISSN:  0168-3659. 
Elzainy, A.A.W.; Gu, X.; Simons, F.E.R. & Simons, K.J., (2003). Hydroxyzine from topical 
phospholipid liposomal formulations: Evaluation of peripheral antihistaminic activity 
and systemic absorption in a rabbit model. The AAPS Journal, Vol. 5, No. 4, pp. 41- 
48,  
Fang, J.Y.; Hong, C.T.; Chiu, W.T. & Wang, Y.Y., (2001). Effect of liposomes and niosomes on 
skin permeation of enoxacin. Int J Pharm, Vol. 219, No. 1-2, pp. 61-72, ISSN:  0378- 
5173. 
Firthouse, P.U.M.; Halith, S.M.; Wahab, S.U.; Sirajudeen, M. & Mohideen, S.K., (2011). 
Formulation and evaluation of miconazole niosomes. Int J PharmTech Res, Vol. 3, No. 2, 
pp. 1019-1022, ISSN:  0974-4304. 
Gašperlin, M. & Gosenca, M., (2011). Main approaches for delivering antioxidant vitamins 
through the skin to prevent skin ageing. Expert Opin Drug Del, Vol. 8, No. 7, pp. 905-919, 
ISSN:  1742-5247. 
Ghafourian, T.; Zandasrar, P.; Hamishekar, H. & Nokhodchi, A., (2004). The effect of 
penetration enhancers on drug delivery through skin: a QSAR study. J Control Release, 
Vol. 99, No. 1, pp. 113-125, ISSN:  0168-3659. 
Gopinath, D.; Ravi, D.; Rao, B.R.; Apte, S.S.; Renuka, D. & Rambhau, D., (2004). Ascorbyl 
palmitate vesicles (Aspasomes): formation, characterization and applications. Int J 
Pharm, Vol. 271, No. 1-2, pp. 95-113, ISSN:  0378-5173. 
Goyal, C.; Ahuja, M. & Sharma, S.K., (2011). Preparation and evaluation of anti-
inflammatory activity of gugulipid-loaded proniosomal gel. Acta Pol Pharm, Vol. 68, No. 
1, pp. 147-150, ISSN:  0001-6837. 
Handjani-Vila, R.M.; Ribier, A.; Rondot, B. & Vanlerberghe, G., (1979). Dispersions of 
lamellar phases of non-ionic lipids in cosmetic products. Int J Cosmetic Sci, Vol. 1, pp. 
303-314,  
Higaki, K.; Nakayama, K.; Suyama, T.; Amnuaikit, C.; Ogawara, K. & Kimura, T., (2005). 
Enhancement of topical delivery of drugs via direct penetration by reducing blood flow 
rate in skin. Int J Pharm, Vol. 288, No. 2, pp. 227-233, ISSN:  0378-5173. 
Hofland, H.; Bowuwstra, J.A.; Ponec, M. Boddé, H.E.; Spies, F.; Coos Verhoef, J.; Junginger 
H.E., (1991). Interactions of non-ionic surfactant vesicles with cultured keratinocytes 
and human skin in vitro: a survey of toxicological aspects  and ultrastructural changes 
in stratum corneum. J Control Release, Vol. 16, No. 1, pp. 155-167, ISSN:  0168-3659. 
 
Niosomes as Carrier in Dermal Drug Delivery 159 
Hofland, H.E.J.; Bouwstra, J.A.; Spies, F. & Bodde, H.E., (1992). Safety aspect of nonionic 
surfactant vesicles- a toxicity study related to the physicochemical characteristics of 
nonionic surfactants. J Pharm Pharmacol, Vol. 44, pp. 287-292, ISSN:  0022-3573 
Hofland, H.E.J.; van der Geest, R.; Bodde, H.E.; Junginger, H.E. & Bouwstra, J.A.,  
(1994). Estradiol permeation from nonionic surfactant vesicles through human  
stratum corneum in vitro. Pharm Res, Vol. 11, No. 5, pp. 659-664, ISSN:  0724- 
8741. 
Hu, C. & Rhodes, D.G., (2000). Proniosomes: a novel drug carrier preparation. Int J Pharm 
Vol. 206, pp. 110-122, ISSN:  0378-5173. 
Jain, C.P.; Vyas, S.P. & Dixit, V.K., (2006). Niosomal system for delivery of rifampicin to 
lymphatics. Indian J Pharm Sci, Vol. 68, No. 5, pp. 575, ISSN:  0250-474X. 
Javadzadeh, Y. & Hamishehkar, H., (2011). Enhancing percutaneous delivery of 
methotrexate using different types of surfactants. Colloid Surface B, Vol. 82, No. 2, pp. 
422-426, ISSN:  0927-7765. 
Javadzadeh, Y.; Shokri, J.; Hallaj-Nezhadi, S.; Hamishehkar, H. & Nokhodchi, A., (2010). 
Enhancement of percutaneous absorption of Finasteride by cosolvents, cosurfactant and 
surfactants. Pharm Dev Technol, Vol. 15, No. 6, pp. 619-625, ISSN:  1083-7450. 
Jayaraman, S.C.; Ramachandran, C. & Weiner, N., (1996). Topical delivery of erythromycin 
from various formulations: An in vivo hairless mouse study. J Pharm Sci, Vol. 85, No. 
10, pp. 1082-1084, ISSN:  1520-6017. 
Jung, S.; Otberg, N.; Thiede, G.; Richter, H.; Sterry, W.; Panzner, S. & Lademann, J., (2006). 
Innovative liposomes as a transfollicular drug delivery system: penetration into porcine 
hair follicles. J Invest Dermatol, Vol. 126, No. 8, pp. 1728-1732, ISSN:  0022-202X. 
Junyaprasert, V.B.; Singhsa, P.; Suksiriworapong, J. & Chantasart, D., (2011). 
Physicochemical properties and skin permeation of span 60/tween 60 niosomes of 
ellagic acid. Int J Pharm, Vol. doi:10.1016/j.ijpharm.2011.11.032, ISSN:  0378- 
5173. 
Kaur, K.; Jain, S.; Sapra, B. & Tiwary, A.K., (2007). Niosomal gel for site-specific sustained 
delivery of anti-arthritic drug: in vitro-in vivo evaluation. Curr Drug Deliv, Vol. 4, No. 4, 
pp. 276-282, ISSN:  1567-2018. 
Kempf, M.; Theobald, U. & Fiedler, H.P., (1999). Economic improvement of the fermentative 
production of gallidermin by Staphylococcus gallinarum. Biotechnol lett, Vol. 21, No. 8, 
pp. 663-667, ISSN: 0141-5492. 
Khan, A.; Sharma, P.K.; Visht, S. & Malviya, R., (2011). Niosomes as colloidal drug  
delivery system: A review. Journal of Chronotherapy and Drug Delivery, Vol. 2, No. 1, pp. 
15-21,  
Kingo, K.; Aunin, E.; Karelson, M.; Philips, M.A.; Rätsep, R.; Silm, H.; Vasar, E.; Soomets, U. 
& Kőks, S., (2007). Gene expression analysis of melanocortin system in vitiligo. J 
Dermatol Sci, Vol. 48, No. 2, pp. 113-122, ISSN:  0923-1811. 
Kirjavainen, M.; Mönkkönen, J.; Saukkosaari, M.; Valjakka-Koskela, R.; Kiesvaara, J. & Urtti, 
A., (1999). Phospholipids affect stratum corneum lipid bilayer fluidity and drug 
 Recent Advances in Novel Drug Carrier Systems 160 
partitioning into the bilayers. J Control Release, Vol. 58, No. 2, pp. 207-214, ISSN:  0168-
3659. 
Kumar, G.P. & Rao, P.R., (2012). Ultra deformable niosomes for improved transdermal drug 
delivery: The future scenario. Asian Journal of Pharmaceutical Sciences, Vol. 7, No. 2, pp. 
96-109, ISSN:  0974-2441  
Lakshmi, P.K. & Bhaskaran, S., (2011). Phase II study of topical niosomal urea gel - an 
adjuvant in the treatment of psoriasis. International Journal of Pharmaceutical Sciences 
Review and Research, Vol. 7, No. 1, pp. 1-7, ISSN:  0976 – 044X  
Lakshmi, P.K.; Devi, G.S.; Bhaskaran, S. & Sacchidanand, S., (2007). Niosomal methotrexate 
gel in the treatment of localized psoriasis: Phase I and phase II studies. Indian J Dermatol 
Venereol Leprol, Vol. 73, No. 3, pp. 157, ISSN:  0378-6323. 
Lala, S.; Pramanick, S.; Mukhopadhyay, S.; Bandyopadhyay, S. & Basu, M.K., (2004). 
Harmine: Evaluation of its antileishmanial properties in various vesicular delivery 
systems. J Drug Target, Vol. 12, No. 3, pp. 165-175, ISSN:  1061-186X. 
Lingan, M.A.; Sathali, A.A.H.; Kumar, M.R.V. & Gokila, A., (2011). Formulation and 
evaluation of topical drug delivery system containing clobetasol propionate niosomes. 
Sci Revs Chem Commun, Vol. 1, No. 1, pp. 7-17,  
Maibach, H.I. & Choi, M.J., (2005). Liposomes and niosomes as topical drug delivery 
systems. Skin Pharmacol Physiol, Vol. 18, pp. 209-219, ISSN:  1660-5527. 
Malhotra, M. & Jain, N.K., (1994). Niosomes as drug carriers. Ind Drugs, Vol. 31, No. 3, pp. 
81-86,  
Mali, N.; Darandale, S. & Vavia, P., (2012). Niosomes as a vesicular carrier for topical 
administration of minoxidil: formulation and in vitro assessment. Drug Deliv Transl Res, 
pp. 1-6, ISSN:  2190-393X. 
Manconi, M.; Sinico, C.; Valenti, D.; Lai, F. & Fadda, A.M., (2006). Niosomes as carriers for 
tretinoin: III. A study into the in vitro cutaneous delivery of vesicle-incorporated 
tretinoin. Int J Pharm, Vol. 311, No. 1-2, pp. 11-19, ISSN:  0378-5173. 
Manconi, M.; Valenti, D.; Sinico, C.; Lai, F.; Loy, G. & Fadda, A.M., (2003). Niosomes as 
carriers for tretinoin: II. Influence of vesicular incorporation on tretinoin photostability. 
Int J Pharm, Vol. 260, No. 2, pp. 261-272, ISSN:  0378-5173. 
Manosroi, A.; Khanrin, P.; Lohcharoenkal, W.; Werner, R.G.; Götz, F.; Manosroi, W. & 
Manosroi, J., (2010). Transdermal absorption enhancement through rat skin of 
gallidermin loaded in niosomes. Int J Pharm, Vol. 392, No. 1, pp. 304-310, ISSN:  0378-
5173. 
Manosroi, A.; Khositsuntiwong, N.; Götz, F.; Werner, R.G. & Manosroi, J., (2009). 
Transdermal enhancement through rat skin of luciferase plasmid DNA loaded in elastic 
nanovesicles. J Liposome Res, Vol. 19, No. 2, pp. 91-98, ISSN:  0898-2104. 
Manosroi, A.; Ruksiriwanich, W.; Abe, M.; Manosroi, W. & Manosroi, J., (2012). 
Transfollicular enhancement of gel containing cationic niosomes loaded with 
unsaturated fatty acids in rice (Oryza sativa) bran semi-purified fraction. Eur J Pharm 
Biopharm, Vol. 81, No. 2, pp. 303-313, ISSN:  0939-6411. 
 
Niosomes as Carrier in Dermal Drug Delivery 161 
Manosroi, A.; Sritapunya, T.; Jainonthee, P. & Manosroi, J., (2008). Anti P. acne activity of 
cream containing aromatic volatile oil from Thai medicinal plants entrapped in 
niosomes for acne treatment.   
Manosroi, A.; Wongtrakul, P.; Manosroi, J.; Midorikawa, U.; Hanyu, Y.; Yuasa, M.; 
Sugawara, F.; Sakai, H. & Abe, M., (2005). The entrapment of kojic oleate in bilayer 
vesicles. Int J Pharm, Vol. 298, No. 1, pp. 13-25, ISSN:  0378-5173. 
Manosroi, J.; Khositsuntiwong, N. & Manosroi, A., (2008). Performance test of gel containing 
extracts from Thai Lanna medicinal plants entrapped in niosomes for hair loss 
treatment.  
Manosroi, J.; Khositsuntiwong, N.; Manosroi, W.; Götz, F.; Werner, R.G. & Manosroi,  
A., (2010). Enhancement of transdermal absorption, gene expression and  
stability of tyrosinase plasmid (pMEL34)-loaded elastic cationic niosomes: Potential 
application in vitiligo treatment. J Pharm Sci, Vol. 99, No. 8, pp. 3533-3541, ISSN:  1520-
6017. 
Messenger, A. & Rundegren, J., (2004). Minoxidil: mechanisms of action on hair growth. Brit 
J Dermatol, Vol. 150, No. 2, pp. 186-194, ISSN:  0007-0963. 
Mura, S.; Pirot, F.; Manconi, M.; Falson, F. & Fadda, A.M., (2007). Liposomes and niosomes 
as potential carriers for dermal delivery of minoxidil. J Drug Target, Vol. 15, No. 2, pp. 
101-108, ISSN:  1061-186X. 
Nasr, M.; Mansour, S.; Mortada, N.D. & Elshamy, A.A., (2008). Vesicular aceclofenac 
systems: A comparative study between liposomes and niosomes. J Microencapsul, Vol. 
25, No. 7, pp. 499-512, ISSN:  0265-2048. 
Nogueira, L.S.; Zancanaro, P.C. & Azambuja, R.D., (2009). [Vitiligo and emotions]. An Bras 
Dermatol, Vol. 84, No. 1, pp. 41-45, ISSN:  1806-4841  
Nounou, M.M.; El-Khordagui, L.K.; Khalafallah, N.A. & Khalil, S.A., (2008). Liposomal 
formulation for dermal and transdermal drug delivery: past, present and future. Recent 
Pat Drug Deliv Formul, Vol. 2, No. 1, pp. 9-18, ISSN:  1872-2113. 
Ogiso, T.; Niinaka, N. & Iwaki, M., (1996). Mechanism for enhancement effect of lipid 
disperse system on percutaneous absorption. J Pharm Sci, Vol. 85, pp. 57-64, ISSN:  1520-
6017. 
Osvaldo, C.; Duarte, A.F.; Paula, Q.; Rosa, A. & Luis, D., (2010). Cutaneous mastocytosis: 
Two pediatric cases treated with topical pimecrolimus. Dermatol Online J, Vol. 16, No. 5, 
pp. 8, ISSN:  1087-2108  
Paolino, D.; Muzzalupo, R.; Ricciardi, A.; Celia, C.; Picci, N. & Fresta, M., (2007). In vitro and 
in vivo evaluation of Bola-surfactant containing niosomes for transdermal delivery. 
Biomed Microdevices, Vol. 9, No. 4, pp. 421-433, ISSN:  1387-2176. 
Pardakhty, A.; Varshosaz, J. & Roulholamini, A., (2007). In vitro study of polyoxyethylene 
alkyl ether niosomes for delivery of insulin. Int J Pharm, Vol. 328, pp. 130-141, ISSN:  
0378-5173. 
Parthasarathi, G.; Udupa, N.; Umadevi, P. & Pillai, G.K., (1994). Niosome encapsulated of 
vincristine sulfate: Improved anticancer activity with reduced toxicity in mice. J Drug 
Target, Vol. 2, No. 2, pp. 173-182, ISSN:  1061-186X. 
 Recent Advances in Novel Drug Carrier Systems 162 
Perrett, S.; Golding, M. & Williams, W.P., (1991). A simple method for the preparation of 
liposomes for pharmaceutical application and characterization of liposomes. J Pharm 
Pharmacol, Vol. 43, pp. 154-161, ISSN:  2042-7158. 
Pugeat, M.; Nicolas, M.H.; Dechaud, H. & Elmidani, M., (1991). Combination of cyproterone 
acetate and natural estrogens in the treatment of hirsutism]. J Gynecol Obst Bior R, Vol. 
20, No. 8, pp. 1057, ISSN:  0368-2315. 
Puglia, C. & Bonina, F., (2012). Lipid nanoparticles as novel delivery systems for cosmetics 
and dermal pharmaceuticals. Expert Opin Drug Del, Vol. 9, No. 4, pp. 429-441, ISSN:  
1742-5247. 
Rahimpour, Y. & Hamishehkar, H., (2012). Liposomes in cosmeceutics. Expert Opin Drug 
Del, Vol. 9, No. 4, pp. 443-455, ISSN:  1742-5247. 
Raja Naresh, R.A.; Pillai, G.K.; Udupa, N. & Chandrashekar, G., (1994). Antiinflammatory 
activity of niosome encapsulated diclofenac sodium in arthitic rats. Indian J Pharmacol, 
Vol. 26, pp. 46-48, ISSN:  0253-7613. 
Rajera, R.; Nagpal, K.; Singh, S.K. & Mishra, D.N., (2011). Niosomes: A controlled and  
novel drug delivery system. Bio Pharm Bull, Vol. 34, No. 7, pp. 945-953, ISSN:  0918- 
6158. 
Ridolfi, D.M.; Marcato, P.D.; Justo, G.Z.; Cordi, L.; Machado, D. & Durán, N., (2011). 
Chitosan-solid lipid nanoparticles as carriers for topical delivery of Tretinoin. Colloid 
Surface B, ISSN:  0927-7765. 
Rita, B. & Lakshmi, P.K., (2012). Preparation and evaluation of modified proniosomal gel for 
localised urticaria and optimisation by statistical method. Journal of Applied 
Pharmaceutical Science, Vol. 2, No. 03, pp. 85-91,  
Rogerson, A.; Cummings, J. & Florence, A.T., (1987). Adriamycin-loaded niosomes: drug 
entrapment, stability and release. J Microencapsul, Vol. 4, No. 4, pp. 321-328, ISSN:  0265-
2048. 
Rubio, L.; Alonso, C.; López, O.; Rodríguez, G.; Coderch, L.; Notario, J.; de la Maza, A. & 
Parra, J.L., (2011). Barrier function of intact and impaired skin: percutaneous 
penetration of caffeine and salicylic acid. Int J Dermatol, Vol. 50, No. 7, pp. 881-889, 
ISSN:  1365-4632. 
Ruckmani, K.; Jayakar, B. & Ghosal, S.K., (2000). Nonionic surfactant vesicles (niosomes) of 
cytarabine hydrochloride for effective treatment of leukemias: Encapsulation, storage, 
and in vitro release. Drug Dev Ind Pharm, Vol. 26, No. 2, pp. 217-222, ISSN:  0363- 
9045. 
Ruksiriwanich, W.; Manosroi, J.; Abe, M.; Manosroi, W. & Manosroi, A., (2011). 5 [alpha]-
Reductase type 1 inhibition of Oryza sativa bran extract prepared by supercritical 
carbon dioxide fluid. J Supercrit Fluid, ISSN:  0896-8446. 
Sahin, N.O. Niosomes as nanocarrier systems. Nanomaterials and nanosystems for 
biomedical applications2007. p. 67-81. 
Sathali, A.A.H. & Rajalakshmi, G., (2010). Evaluation of transdermal targeted niosomal drug 
delivery of terbinafine hydrochloride. Int J PharmTech Res, Vol. 2, No. 3, pp. 2081-2089, 
ISSN:  0974-4304. 
 
Niosomes as Carrier in Dermal Drug Delivery 163 
Schreier, H. & Bouwstra, J., (1994). Liposomes and niosomes as topical drug carriers: dermal 
and transdermal drug delivery. J Control Release, Vol. 30, No. 1, pp. 1-15, ISSN:  0168-
3659. 
Shahiwala, A. & Misra, A., (2002). Studies in topical application of niosomally entrapped 
nimesulide. J Pharm Pharm Sci, Vol. 5, No. 3, pp. 220, ISSN:  1482-1826. 
Shatalebi, M.A.; Mostafavi, S.A. & Moghaddas, A., (2010). Niosome as a drug carrier for 
topical delivery of N-acetyl glucosamine. Res Pharm Sci, Vol. 5, No. 2, pp. 107, ISSN:  
1735-5362. 
Shi, B.; Fang, C.; You, M.X. & Pei, Y.Y., (2005). Influence of PEG chain length on in  
vitro drug release and in vivo pharmacokinetics of hydroxycamptothecin (HCPT) 
loaded PEG-PHDCA niosomes. Chinese Pharmaceutical Journal, Vol. 40, No. 21, pp. 1643-
1646,  
Su, Y.H. & Fang, J.Y., (2008). Drug delivery and formulations for the topical treatment of 
psoriasis. Expert Opin Drug Del, Vol. 5, No. 2, pp. 235-249, ISSN:  1742-5247. 
Tabbakhian, M.; Tavakoli, N.; Jaafari, M.R. & Daneshamouz, S., (2006). Enhancement of 
follicular delivery of finasteride by liposomes and niosomes:: 1. In vitro permeation and 
in vivo deposition studies using hamster flank and ear models. Int J Pharm, Vol. 323, 
No. 1-2, pp. 1-10, ISSN:  0378-5173. 
Uchegbu, I.F. & Duncan, R., (1997). Niosomes containing N-(2-hydroxypropyl) 
methacrylamide copolymer-doxorubicin (PK1): effect of method of preparation and 
choice of surfactant on niosome characteristics and a preliminary study of body 
distribution. Int J Pharm, Vol. 155, No. 1, pp. 7-17, ISSN:  0378-5173. 
Varshosaz, J.; Pardakhty, A.; Mohsen, S. & Baharanchi, H., (2005). Sorbitan monopalmitate-
based proniosomes for transdermal delivery of chlorpheniramine maleate. Drug Deliv, 
Vol. 12, No. 2, pp. 75-82, ISSN:  1071-7544. 
Venuganti, V.V. & Perumal, O.P. Nanosystems for dermal and transdermal drug delivery. 
In: Pathak Y, Thassu D, editors. Drug delivery nanoparticles formulation and 
characterization. New York: Informa Healthcare USA, Inc; 2009. p. 126-155. 
Verma, A.K. & Bindal, M., (2012). A review on niosomes: an ultimate controlled and novel 
drug delivery carrier. Int J Nanoparticles Vol. 5, No. 1, pp. 73-87,  
Vyas, J.; Vyas, P.; Raval, D. & Paghdar, P., (2011). Development of topical niosomal gel of 
benzoyl peroxide. ISRN Nanotechnology, Vol. 2011, ISSN:  2090-6064. 
Weiner, N., (1998). Targeted follicular delivery of macromolecules via liposomes. Int J 
Pharm, Vol. 162, No. 1-2, pp. 29-38, ISSN:  0378-5173. 
Yadav, J.D.; Kulkarni, P.R.; Vaidya, K.A. & Shelke, G.T., (2011). Niosomes: a review. J Pharm 
Res, Vol. 4, pp. 632-636, ISSN:  0974-6943. 
Yoshida, H.; Lehr, C.M.; Kok, W.; Junginger, H.E.; Verhoef, J.C. & Bouwstra, J.A., (1992). 
Niosomes for oral delivery of peptide drugs. J Control Release, Vol. 21, No. 1-3, pp. 145-
153, ISSN:  0168-3659. 
Yoshioka, T.; Sternberg, M.; Moody, M. & Florence, A.T., (1992). Niosomes from Span 
surfactants: Relations between structure and form. J Pharm Pharmacol, Vol. 44, pp. 1044-
1044, ISSN:  0022-3573. 
 Recent Advances in Novel Drug Carrier Systems 164 
Zhang, X.J.; Chen, J.J. & Liu, J.B., (2005). The genetic concept of vitiligo. J Dermatol Sci, Vol. 
39, No. 3, pp. 137-146, ISSN:  0923-1811. 
